The ISOC2 (Immune Suppressive and Oncogenic Signaling Component 2) antibody is a tool developed to study the ISOC2 protein, which has garnered attention for its potential roles in immune regulation and cancer biology. ISOC2. also known as C1orf109. is a relatively understudied protein encoded by a gene located on human chromosome 1. Emerging evidence suggests its involvement in modulating immune responses, particularly through interactions with signaling pathways like NF-κB or MAPK, which are critical in inflammation and oncogenesis. ISOC2 has been implicated in promoting tumor progression by enhancing immune evasion mechanisms, potentially via suppression of T-cell activity or upregulation of checkpoint molecules. The ISOC2 antibody, typically generated in rabbit or mouse models, enables detection and quantification of ISOC2 expression in tissues or cell lines using techniques such as Western blotting, immunohistochemistry, and flow cytometry. Recent studies highlight its overexpression in certain cancers, including breast and colorectal carcinomas, correlating with poor prognosis. However, its precise molecular mechanisms and physiological functions remain unclear, necessitating further research. The availability of ISOC2 antibodies facilitates exploration of its role in tumor microenvironments, immune cell interactions, and therapeutic targeting. Ongoing efforts aim to validate its specificity and utility in diagnostic or prognostic applications, as well as in preclinical models for immunotherapy development.